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Background: The wnt/β-catenin signaling pathway is known to affect in cancer oncogenesis and progression by
interacting with the tumor microenvironment. However, the roles of wnt3a and wnt5a in colorectal cancer (CRC)
have not been thoroughly studied. In the present study, we investigated the expression of wnt protein and the
concordance rate in primary tumor and metastatic sites in CRC. To determine the relationship of wnt proteins with
invasion related protein, we also analyzed the association between wnt protein expression and the expression of
matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor receptor-2 (VEGFR-2).
Methods: Tumor tissue was obtained from eighty-three paraffin- embedded blocks which were using resected
tissue from both the primary tumor and metastatic sites for each patient. We performed immunohistochemical
staining for wnt3a, wnt5a, β-catenin, MMP-9 and VEGFR-2.
Results: Wnt3a, wnt5a, β-catenin, and MMP-9 expression was high; the proteins were found in over 50% of the
primary tumors, but the prevalence was lower in tissue from metastatic sites. The concordance rates between the
primary tumor and metastatic site were 76.2% for wnt5a and 79.4% for wnt3a and β-catenin, but VEGFR-2 was
expressed in 67.4% of the metastatic sites even when not found in the primary tumor. Wnt3a expression in primary
tumors was significantly associated with lymph node involvement (p = 0.038) and MMP-9 expression in the primary
tumor (p = 0.0387), mesenchyme adjacent to tumor (p = 0.022) and metastatic site (p = 0.004). There was no other
relationship in the expression of these proteins. Vascular invasion in primary tumor tissue may be a potential prognostic
marker for liver metastasis, but no significant association was observed among the wnt protein, MMP-9, and VEGFR-2 for
peritoneal seeding. In survival analysis, β-catenin expression was significantly correlated with overall survival (p = 0.05).
Conclusions: Wnt3a and wnt5a expression had a concordance rate higher than 60% with a high concordance rate
between the primary tumor and metastatic site. Wnt3a expression is associated with the expression of MMP-9 in primary
tumor tissue adjacent mesenchymal tissue, and at the metastatic site. As a prognostic marker, only β-catenin expression
showed significant relation with survival outcome.
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Colorectal cancer (CRC) is the 3rd most common cancer
in Korea and is becoming more common in Asia and
Western countries [1]. As new anti-cancer agents and
new technology for local treatment have been developed,
the survival rates of patients with CRC have been* Correspondence: angelamd@catholic.ac.kr
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reproduction in any medium, provided the orincreasing, even for patients with stage IV cancer. How-
ever, distant organ metastasis eventually develops in stage
IV cancer, and leads to fatal organ failure. To improve
survival outcomes, it is important to control cancer
invasion and metastasis, but the mechanisms by which
CRC becomes metastasis are not yet known.
The wnt/β-catenin pathway is known to play an import-
ant role in maintaining cell homeostasis in normal cells
and in embryologic cell development. In CRC, mutation
in APC or β-catenin, component of the wnt signaling. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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some sporadic CRC cases. Recently, many researchers
have suggested that the wnt signaling pathway is also
involved in controlling cancer cell invasion and metas-
tasis by interacting with the tumor microenvironment
or other signal pathways [2-4]. However, most studies
investigating the effects of the wnt pathway on CRC
have focused on β-catenin, and the role of wnt3a (the
initiator of wnt/β-catenin pathway) is not well understood.
The non-canonical pathway via wnt5a is another of
the identified wnt signaling pathways. The non-canonical
pathway plays a role in embryonic cell motility, but the
role of the non-canonical pathway in cancer is unknown.
Katoh has suggested that the non-canonical pathway is
involved in tumor cell invasion and metastasis [5], but
studies investigating the role of wnt5a expression in
cancer have been limited and controversial. Several
authors have reported that the wnt5a expression is
associated with higher grade, poor differentiation or
poor clinical outcomes, but others have suggested that
wnt5a expression antagonizes the wnt/β-catenin pathway
and inhibits oncogenesis [6]. Dejimek et al. suggested that
wnt5a expression in stage II colon cancer is associated
with good prognosis, and another study reported that
wnt5a methylation is associated with microsatellite in-
stability and BRAF mutation [7,8]. Considering these
data, the exact role of wnt5a in cancer is unclear.
MMP-9 and VEGF expression are commonly studied
in cancer research, and their expression is associated with
invasion and metastasis. One study reported that in vitro
inhibition of DKK-1 signaling inhibits the MMP-9 expres-
sion [9], but MMP-9 expression decreased after wnt3a
treatment in another study [10]. Many studies investigat-
ing the role of MMP-9 in CRC have been conducted using
cell lines or animal models. Few trials have reported that
MMP-9 expression can be used as a prognostic factor
for disease recurrence in human tissue [11]. Thus, the
association between the wnt signaling pathway and MMP-
9 and VEGFR-2 expression in CRC remains unclear.
Previous experiments investigating the role of the
wnt proteins in metastasis have been conducted at the
primary site of stages I-III CRC because diseased tissue
can be easily obtained through surgery. Studies focusing
on the relationships between the primary tissue and tissue
from the metastatic site have rarely been reported.
Recently, resection of metastatic lesions has become a
treatment option for patients with stage IV CRC. In the
present study, we evaluated the expression of wnt3a,
wnt5a, MMP-9, and VEGFR-2 in human tissue from
primary and metastatic sites of stage IV advanced CRC
patients to identify associations between these proteins.
We also analyzed the concordance between the primary
and metastatic lesions, and aimed to identify the potential
prognostic markers of survival outcome.Methods
Patients
This study included eighty-three patients with colon or
rectal cancer who had resection for both a primary mass
and metastatic lesions resected in a single procedure at
Seoul St. Mary’s Hospital between January 2000 and
December 2006. All patients had colorectal cancer with
organ metastasis at the initial diagnosis. Clinical records
and pathological reports were reviewed retrospectively.
This study was approved by the institutional review board
of Seoul St. Mary’s hospital (KC10SIMI0621).
Tissue microarray (TMA) and immunohistochemical staining
Core biopsies with 3.0 mm diameter were taken from
representative areas of tumor tissue. Each patient had
biopsy samples taken from the primary tumor mass
and its adjacent mesenchyme as well as the metastatic
site and its adjacent mesenchyme. Tissue cores from
each specimen were assembled on a recipient paraffin
block with a precision instrument (Micro Digital Co.
Korea), following previously established methods [12].
We performed immunohistochemical staining on 5 μm
sections of the TMA blocks. Each paraffin section was
deparaffinized for 1 hour at 60°C in xylene and rehydrated
in serial graded ethanol before being stored overnight in
citrate buffer (0.01 M, pH 6.0) at 75°C for antigen retrieval.
Endogenous peroxidase activity was blocked with 0.3%
hydrogen peroxide in methanol. Sections were incubated
for 1 hour at room temperature with the following
primary antibodies at the specified dilutions: Wnt3a
(Abcam, Cambridge, UK) diluted 1:100, Wnt5a (Abcam,
Cambridge, UK) diluted 1:50, β-catenin (Abcam, Cambridge,
UK) diluted 1:100, MMP-9 (Cell Signaling, Danvers,
MA, USA) diluted 1:100, and VEGFR-2 (Cell Signaling,
Danvers, MA, USA) diluted 1:200. Immunohistochemical
staining was performed using the rabbit or mouse DAKO
ChemMate TM EnVision TM system and a Peroxidase/
DAB kit (DAKO). Sections were then counterstained with
Mayer hematoxylin and dehydrated, cleared and mounted.
The results were interpreted by two independent pa-
thologists who were blinded to the specific diagnosis
and prognosis for each case. The staining intensity was
scored on a three-tiered scale: score 0 = less than 10% of
cells positive; 1 = 10–49% positive; and 2 =more than
50% of cells positive. The criterion for positive staining
was more than 1+ of tumor cells that showed distinct
nuclear or cytoplasmic staining (Figure 1).
Statistical analysis
Continuous and categorical variables were compared
using the Student’s t test and chi-square test. All statis-
tical analyses were performed using SPSS (version 13.0)
and p value under 0.05 was considered statistically
significant.
Figure 1 Immunohistochemical staining for the wnt3a, wnt5a, β-catenin, MMP-9, and VEGFR-2 (magnification x 200).
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Patient characteristics and protein expression
Of the 83 patients, 46 were male and the median age
was 60 years. Liver metastasis was the most common
(57.8%), followed by peritoneum metastasis (26.5%).
Thirteen patients had no lymph node involvement even
with stage IV disease, and two patients had T2 disease.
The patient characteristics are summarized in Table 1.
Wnt3a, wnt5a, MMP-9 and β-catenin were expressed
in more than 50% of the primary tumors, but VEGFR-2
was not. These protein expression levels were slightly
decreased in the tissue taken from the metastatic sites
(Table 2). We analyzed the concordance rate of the
protein expression between the primary tumor and
metastatic site. The concordance rates of wnt3a, wnt5a
and β-catenin expression were high; all of the rates
were in the range of 76.2% to 79.4%, and MMP-9
expression had a 68.3% concordance rate. However,
VEGFR-2 was expressed in 67.4% of the metastatic sites
when there was no expression in the primary tumors,
with only a 40.0% concordance rate between primary
tumor and metastatic sites.Wnt3a expression in primary tumor correlated with
lymph node involvement and MMP-P expression
We analyzed the association between wnt expression in
the primary tumor and the clinicopathologic findings,
including the T & N stage. Wnt3a expression in the
primary tumor was significantly correlated with lymph
node involvement (p = 0.038) and MMP-9 expression
in primary, adjacent mesenchyme and metastatic sites
(p = 0.038, 0.022 and 0.004, respectively). There was no
association between wnt5a expression and other findings,
but wnt5a expression did show a correlation tendency
with lymph node and lymphatic invasion. This result is
summarized in Table 3.
Analysis of liver or peritoneal metastasis, wnt expres-
sion, MMP expression, and VEGFR-2 expression in
the primary tumor did not show any associations but
venous invasion was associated with liver metastasis
(p = 0.047). We also performed immunohistochemical
staining of the adjacent mesenchymal tissue, but there
was no association between wnt3a, wnt5a, MMP, or
VEGFR-2 expression and liver or peritoneal metastasis
(Table 4).
Table 1 Patients’ characteristics
Number
Age Years 60 (27–78)
Sex M : F 46 : 37
Location Colon 51 (61.4%)
Rectum 32 (38.6%)
T 2 2 (2.4%)
3 24 (28.9%)
4 57 (68.7%)
N 0 13 (15.7%)
1 26 (31.3%)
2 44 (53.0%)





Table 3 The association of wnt expression in primary
tumor and other pathologic findings
Wnt3a Wnt5a
No. p No. p
T 2 1 0
3 13 0.626 17 0.092
4 37 41
N 0 8 9
1 21 0.038 19 0.910
2 22 30
Grade Well 6 6
Moderate 37 0.268 45 0.945
Poorly 8 7
Lymphatic invasion (+) 46 0.482 54 0.088
Venous invasion (+) 16 0.594 20 0.249
Perineural invasion (+) 34 0.060 37 0.136
Primary tumor β-catenin 46 0.063 52 0.054
MMP-9 34 0.004 33 0.306
VEGFR-2 21 0.166 24 0.102
Adjacent β-catenin 39 0.299 37 0.289
Mesemchyme MMP-9 32 0.022 32 0.359
VEGFR-2 15 0.205 17 0.158
Metastatic site β-catenin 29 0.382 32 0.598
MMP-9 23 0.031 20 0.511
VEGFR-2 16 0.396 15 0.364
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staining in primary tumors showed significantly poorer
survival outcomes than those with no staining (18.4 months
vs. 42.9 months, respectively, p = 0.05, Figure 2). There
were no other prognostic factors for survival.
Discussion
The wnt/β-catenin signaling pathway is an emerging
target for cancer research; studies indication the path-
way may play a role in cancer invasion and progression
by interacting with the tumor microenvironment and
oncogenesis [13]. Wnt/β-catenin has been widely studied
as a prognostic factor for CRC, and it may also be involved
in the mechanism of cancer invasion [14,15]. However,
research has focused on aberrant nuclear β-catenin rather
than wnt3a, despite the role of wnt3a as a major initiating
factor in the wnt/β-catenin pathway. In the present study,
we analyzed wnt3a and wnt5a to determine their roles in
cancer progression. We selected the patients who had had
both their primary tumor and the metastatic sites resected
to identify differences in the protein expression between
the primary and the metastatic sites. Expression of wnt3a
was very high in tissues from both primary tumors and
metastatic sites but was higher at the primary site with a
concordance rate higher than 70%. Wnt expression at
the metastatic site was rare if the primary tumor testedTable 2 Immunohistochemical staining for primary tumors an
Wnt3a Wnt5a
Primary tumor 51 (61.4%) 58 (69.9%)
Metastatic site 38 (45.8%) 39 (47.0%)
Concordance rate 79.4% 76.2%negative for both wnt3a and wnt5a. This result suggests
that wnt could be expressed initially when CRC develops,
not newly emerged as the cancer progresses. This result is
consistent with the previous studies on the oncogenic role
of the wnt signaling pathway in various cancers [16,17].
Recently, Boutros reported that sustained wnt activity
through wnt3a and Evi/Wls/GPR177 can be important
for the proliferation in colon cancer cell, independently
from APC or β-catenin mutation [18]. It suggests that
the upper stream factor of wnt signaling pathway may
play an important role in the cancer progression.
It is well understood that MMP-9 overexpression is a
key factor in degradation of the extracellular matrix, an
essential step in tumor invasion and metastasis; this role
has been observed in human tissue and cell line studies
of CRC [19,20]. In the present study, wnt3a expression
was significantly correlated with MMP-9 expression in thed metastatic site
β-catenin MMP-9 VEGFR-2
70 (84.3%) 45 (54.2%) 30 (36.1%)
44 (53.0%) 28 (33.7%) 22 (26.5%)
79.4% 68.3% 40.0%
Table 4 The association between the protein expression
and liver or peritoneal seeding
Liver Peritoneum
No. p No. p
T 2 1 0
3 18 0.130 4 0.264
4 29 18
N 0 6 2
1 17 0.508 5 0.243
2 25 15
Grade Well 4 3
Moderate 39 0.749 17 0.419
Poorly 5 2
Lymphatic invasion (+) 44 0.304 20 0.556
Venous invasion (+) 19 0.047 5 0.230
Perineural invasion (+) 27 0.353 15 0.223
Primary tumor Wnt3a 30 0.498 13 0.493
Wnt5a 34 0.506 12 0.062
β-catenin 39 0.277 18 0.470
MMP-9 26 0.584 10 0.238
VEGFR-2 15 0.196 9 0.385
Adjacent mesenchyme Wnt3a 18 0.498 11 0.151
Wnt5a 29 0.298 15 0.412
β-catenin 36 0.453 15 0.347
MMP-9 25 0.510 12 0.533
VEGFR-2 13 0.431 5 0.494
Figure 2 Overall survival according to β-catenin expression.
β-catenin-expressing group in primary tumor showed poorer survival
outcome than non-expressing group (18.4 vs. 42.9 months, p = 0.05).
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previous study, inhibition of the wnt/β-catenin pathway
decreased the level of MMP-9 mRNA in embryonic neural
stem cells [9]. These data suggest that the wnt/β-catenin
signaling pathway may have an effect on MMP-9 ex-
pression, with a role in cancer invasion and metastasis.
However, in one mouse study, wnt3a stimulation was
shown to inhibit MMP-2 and MMP-9 expression in
mesenchymal stem cells; the investigator suggested that
regulation of wnt3a could be different in mice and human
[13]. Recently, some studies have reported that inhibition
of β-catenin by some agents can also inhibit MMP-2 or
MMP-9 expression [21,22]. The previous data suggest
that the wnt/β-catenin pathway may play a role in cancer
invasion and metastasis through MMP-9 expression.
VEGFR is also a topic of interest in cancer proliferation
and metastasis research. Many studies have associated
the wnt/β-catenin signaling pathway with VEGFR activity
[23,24]. In this study, however, wnt expression was not
correlated with VEGFR-2 expression. In addition, VEGFR-
2 expression was relatively low in our study, particularly
at the metastatic site. In other experiments, VEGFR-1
expression was regulated independent of the wnt/β-ca-
tenin pathway, and VEGFR-2 did not show any signifi-
cant association with lymph node or lymphovascular
invasion [25,26]. Based on these data, the mechanism
by which VEGFR is involved in metastasis should be
explored independently of the wnt signaling pathway.
Wnt5a is a key initiating factor in the non-canonical
pathway, but its role in cancer is not known. Kato has
suggested that the non-canonical pathway may be involved
in cancer cell invasion [5]. In previous study, wnt5a expres-
sion showed aggressive behavior in breast or gastric cancer
[27,28]. However, wnt5a has also been associated with a
good prognosis or tumor suppression by inhibiting the
wnt/β-catenin pathway in CRC [7,29]. In our study, wnt5a
showed no correlation with pathologic findings or invasion
related protein expression, but showed higher expression
in the primary and metastatic tumor sites. The data do
not show an antagonistic relationship between wn3a
and wnt5a in the present study. To determine the role
of wnt5a in CRC, further analysis of other signaling
pathways is warranted.
Theoretically, wnt3a expression is directly associated
with β-catenin expression. However, previous studies have
reported that β-catenin can be independently, aberrantly
expressed without altering wnt3a in CRC [14,15] and could
not be differentiated from the β-catenin that is activated by
wnt3a. This is the reason β-catenin was higher than wnt3a
expression in our study. In survival analysis of our study, β-
catenin expression was significantly correlated with poor
survival outcome, independently of wnt3a expression. It
has previously been shown that the β-catenin expression
can be independent prognostic marker for CRC patients.
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expression was significantly correlated only with the sur-
vival outcome. Known prognostic factors, such as lymph
node involvement or lymphovascular invasion, did not
show any significance in our survival analysis. We analyzed
the stage IV patients with metastasis in the present study;
these factors could have less of effect on the survival status
in stage IV patients than in stage II or III CRC patients.
There is a limitation in our study. We could not deter-
mine whether the wnt and MMP-9 expression levels are
prognostic or predictive factors because we performed
the present study in stage IV CRC patients. According
to the objective of this study, we enrolled the patients
who underwent surgery for primary and metastatic sites;
thus, patients with early stages of CRC were not included.
Therefore, a comparative study would be required to de-
termine whether wnt and MMP-9 expression levels are
prognostic factors for the recurrence of distant metastasis.
In summary, wnt3a and wnt5a expression is high in
primary and metastatic tumors in CRC with a high con-
cordance rate. The wnt3a expression is highly correlated
with MMP-9 expression, but not with VEGFR-2, and we
did not determine the role of wnt5a. To investigate the
mechanism of invasion and metastasis, further studies
of the wnt/β-catenin pathway and MMP-9 should be
performed, and another approach for evaluating VEGFR
or wnt5a should be explored.
Conclusions
Wnt3a and wnt5a are highly expressed in colorectal cancer
both in primary and metastatic sites with a higher than
50% concordance rate. The wnt3a expression is signifi-
cantly associated with MMP-9 expression, the metastasis
related protein, but is not related with VEGFR-2 expres-
sion, and other metastatic related protein.
Abbreviation
CRC: Colorectal cancer; MMP-9: Matrix metalloprroteinase-9; TMA: Tissue
microarray; VEGF: Vascular endothelial growth factor; VEGFR: Vascular
endothelial growth factor receptor.
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